Study by the Brubaker Lab may help explain increased diabetes risk in shift-workers

Professor Pat Brubaker's lab recently published a new study in the American Diabetes Association journal. Professor Brubaker explains:

"Glucagon-like peptide1 (GLP-1) is an intestinal hormone that exerts anti-diabetic effects, and long-acting GLP-1 mimetics are therefore used to treat patients with type 2 diabetes.

This study demonstrates that GLP-1 is released with a circadian, 24-hr pattern in mice, that is controlled by the intestinal microbiota.

The study further showed that this pattern of GLP-1 secretion is important for the maintenance of normal insulin and glucose levels in the blood throughout the day-night cycle.

The findings may help explain the increased risk for metabolic diseases such as type 2 diabetes in individuals with circadian disruption, as found in shift-workers." 

Click here to read the full study

Congratulations to the whole team!